SANTA ANA, CA--(Marketwired - Dec 14, 2015) - BioLargo, Inc.'s (
Dr. Richard Smith, President of BioLargo Water, Inc., commented, "This funding allows us to conduct synchrotron studies at the Canadian Light Source (www.lightsource.ca), to hire additional staff, including two PhDs, and to support further development of our technology and AOS filter over the next 18 months."
Dennis Calvert, President and CEO of BioLargo, added, "We are thankful for continued financial support of the NRC-IRAP program. Their support is critical to advance our plans to grow and generate profits through our continued development and commercialization of our innovative AOS filter technology."
About BioLargo, Inc.
BioLargo, Inc. (BLGO) makes life better by delivering technology-based products that help solve some of the world's most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. The subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter, a product being developed specifically to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. It is the winner of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil industry. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2016.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2014.